Cargando…
Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study
BACKGROUND: Patients with in‐transit melanoma metastases frequently experience high rates of recurrence, limited overall survival and reduced quality of life. After promising results within a Phase II, multi‐center study, PV‐10 treatment was continued at our institution for patients with in‐transit...
Autores principales: | Read, Tavis A., Smith, Aaron, Thomas, Janine, David, Michael, Foote, Matthew, Wagels, Michael, Barbour, Andrew, Smithers, B. Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668008/ https://www.ncbi.nlm.nih.gov/pubmed/29529343 http://dx.doi.org/10.1002/jso.24921 |
Ejemplares similares
-
Results of a phase II, open‐label, non‐comparative study of intralesional PV‐10 followed by radiotherapy for the treatment of in‐transit or metastatic melanoma
por: Foote, Matthew, et al.
Publicado: (2017) -
Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
por: Read, Tavis, et al.
Publicado: (2017) -
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014) -
Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014) -
Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream
por: Leventhal, Jonathan S., et al.
Publicado: (2016)